Biotronik said today it launched its Edora HF-T magnetic resonance-conditional quadripolar cardiac resynchronization therapy pacemaker, touting it as the smallest device of its type available in the US.

The German medical device company said the Edora HF-T QP has a volume of 15 cc, making it the smallest MR conditional CRT-P available in the US. The device has a lifespan of 10 years and features MRI Autodetect, Closed Loop Stimulation and Biotronik Home Monitoring technology, the company said.

“Patient care is a constant journey. It doesn’t end when the patient leaves my office or recovers from a procedure. As healthcare providers, we must think beyond today and help ensure patients are appropriately cared for throughout their lifetime. MR conditional CRT-Ps that can be programmed to automatically switch to MRI mode when they enter the MRI environment are another significant step in delivering the best possible care throughout the patient journey. This technology eliminates an office visit for patients and decreases administrative burden for providers. The impact is significant, especially in institutions that perform cardiac MRI for advanced ventricular care,” cardiac electrophysiologist Dr. Roderick Tung said in a prepared statement.

Biotronik’s MRI Autodetect technology is designed to minimize the time the device is in MRI mode, and after being activated by a clinician, can automatically recognize when a patient enters an MRI field to change the device programming into MRI mode, the company said.

“With the launch of Edora HF-T QP, Biotronik offers a full suite of ProMRI products ensuring physicians can always choose MRI conditional devices for their patients. Our devices are the only FDA-approved CRM solutions that provide automatic detection of an MRI environment, physiologic rate adaptation and automatic daily remote monitoring. These are differentiators that contribute to personalized and preventive care that impacts long-term health outcomes,” Biotronik prez Marlou Janssen said in a press release.

In July, Biotronik said it won FDA approval for its Intica DX and Intica cardiac resynchronization therapy CRT-DX implantable cardioverter defibrillator systems and that it launched the devices in the US.